サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1775063

十二指腸潰瘍治療の世界市場

Duodenal Ulcer Treatment

出版日
ページ情報
英文 380 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
十二指腸潰瘍治療の世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 380 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

十二指腸潰瘍治療の世界市場は2030年までに50億米ドルに達する見込み

2024年に45億米ドルと推定される十二指腸潰瘍治療の世界市場は、2024～2030年の分析期間においてCAGR 2.0%で成長し、2030年には50億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロトンポンプ阻害薬は、CAGR 1.3%を記録し、分析期間終了時には22億米ドルに達すると予測されます。H2拮抗薬セグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 3.8％で成長予測

米国の十二指腸潰瘍治療市場は2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを3.8%として、2030年までに9億3,600万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7%と1.4%と予測されています。欧州では、ドイツがCAGR 1.0%で成長すると予測されています。

世界の十二指腸潰瘍治療市場- 主要動向と促進要因のまとめ

なぜ十二指腸潰瘍治療は多面的な治療へと進化しているのか？

十二指腸潰瘍治療は、基本的な症状の緩和から、根本的な原因の特定、再発の抑制、合併症の予防を目的とした包括的な多因子アプローチへと大きく変化しています。歴史的には制酸剤と食事療法が中心であったが、現在の治療戦略にはプロトンポンプ阻害薬（PPI）、H2受容体拮抗薬、ヘリコバクター・ピロリ除菌用抗生物質、粘膜保護薬、併用療法などの広範な医薬品が含まれています。ピロリ菌が原因菌として発見され、酸の抑制とともに除菌という臨床的パラダイムが根本的にシフトしたことが、この進化に拍車をかけた。さらに、抗生物質耐性や治療の失敗に対処するために、2種類の抗生物質と制酸剤を組み合わせた3剤併用療法や4剤併用療法が好まれるようになってきています。一部の薬剤は市販されるようになり、利用しやすくなったが、長期的な治癒とコンプライアンスを確保するため、医師主導の治療レジメンに再び注目が集まっています。治療範囲は薬物療法にとどまらず、生活習慣のカウンセリング、食事指導、経過観察のための内視鏡検査など、患者のケアに欠かせないものとなりつつあります。遅延放出カプセルや口腔内崩壊錠などのドラッグデリバリーシステムの革新も、患者のアドヒアランスと治療成績を向上させています。これらを総合すると、治療状況は個別化医療、感染管理、症状コントロール戦略の交差点を反映していることになります。

テクノロジーは診断と治療モニタリングにおける臨床実践をどのように再定義しているか？

近年、十二指腸潰瘍治療で採用されている診断とモニタリングのツールは著しく改善され、臨床上の意思決定とフォローアップ・ケアに変化をもたらしています。尿素呼気試験、便中抗原検査、高度な血清学的検査などの非侵襲的診断ツールの普及により、十二指腸潰瘍の主な原因であるピロリ菌感染の早期発見率が大幅に向上しました。より複雑な症例や再発を繰り返す症例では、診断だけでなく治療後の粘膜治癒をモニターするために、高解像度画像や生検機能を備えた内視鏡技術が活用されています。電子カルテやAIによる症状追跡を含むデジタルヘルスツールは、消化器内科医が治療レジメンをより効果的に個別化することを可能にしつつあります。さらに、ファーマコゲノミクスは、個々の患者における抗生物質の有効性と耐性パターンを決定する重要な要因として浮上しており、治療が的を絞ったものであるだけでなく、持続的な寛解をもたらすものであることを保証しています。遠隔医療プラットフォームの台頭も、特に遠隔地における消化器診察へのアクセスを拡大し、潰瘍症状のタイムリーな診断と管理を容易にしています。さらに、服薬リマインダー、食事モニタリング、症状ログに焦点を当てたモバイルヘルスアプリは、再発予防に不可欠な患者のアドヒアランスをサポートしています。このような技術により、世界中のヘルスケアシステムで十二指腸潰瘍の治療、モニタリング、管理方法が再構築されつつあります。

ライフスタイルの変化とリスクプロファイルが市場シフトに果たす役割とは？

現代のライフスタイルの変化は、十二指腸潰瘍の治療パターンを変化させる原因としても結果としても浮上しています。ストレス、不規則な食習慣、飲酒量の増加、喫煙、非ステロイド性抗炎症薬（NSAIDs）の多用は、世界の十二指腸潰瘍の発生に大きく寄与しています。このような疫学的変化により、若年層、女性、従来とは異なる患者層など、より広範な層が影響を受けています。その結果、早期介入戦略、予防スクリーニング、全人的治療モデルに対する需要が高まっています。デジタルメディアやヘルスケア・アウトリーチ・プログラムに後押しされ、消化管の健康に対する一般市民の意識が高まっているため、症状発現時に診断を求める人が増えており、診断薬と治療薬の両市場需要を押し上げています。一方、ヘルスケア業界は予防医療に重点を置いているため、消化器診察や内視鏡処置に対する保険適用が拡大し、治療への障壁が低くなっています。これと並行して、製薬会社は潰瘍の症状やリスクに関する認識を高めるキャンペーンに投資しており、診断薬や治療薬の普及をさらに促進しています。患者の期待が、より早い回復、より少ない副作用、日常生活への最小限の支障へと進化するにつれ、治療ソリューションは、忍容性の向上と再発率の減少を伴う包括的なケアを提供するよう再調整されています。

十二指腸潰瘍治療市場の需要拡大の要因は？

十二指腸潰瘍治療市場の成長は、技術の進歩、治療プロトコルの変化、ヘルスケアインフラの改善、患者行動の進化に関連するいくつかの要因によってもたらされます。特に、衛生状態がまだ改善されておらず、認知度が比較的低い発展途上国におけるピロリ菌感染の世界の有病率の上昇は、中心的な成長要因の1つです。このためヘルスケアプロバイダーは、より広範な検査と的を絞った抗生物質療法への投資を余儀なくされています。もう一つの主要な推進力は、標準的な抗生物質に対する耐性の増加であり、新規薬剤の組み合わせ、セカンドライン治療オプション、新しい抗生物質クラスといった形で、医薬品の技術革新を促しています。リアルタイムPCR検査や高解像度内視鏡検査などの高度な診断ツールがより広く利用可能になり、統合されたことで、より早期かつ正確な診断が可能になり、タイムリーで効果的な治療を受ける患者数が増加しています。さらに、公衆衛生への取り組み、保険の普及、遠隔医療プラットフォームによって、新興市場におけるヘルスケアへのアクセスが拡大し、診断率と治療率が大幅に向上しています。非侵襲的な外来ベースの治療に対する患者の需要は、利便性の高い製剤や治療レジメンの開発を促しています。さらに、北米、欧州、アジアの一部などの地域では高齢化が進んでおり、非ステロイド性抗炎症薬（NSAID）の使用が増加しているため潰瘍になりやすく、一貫した需要を牽引しています。これらの要因は、予防ヘルスケアへの動向や胃腸の健康に対する支出の増加とともに、世界の十二指腸潰瘍治療市場の成長を加速させています。

セグメント

治療薬（プロトンポンプ阻害薬、H2拮抗薬、抗生物質、その他）、投与経路（経口剤、非経口剤）、流通チャネル（病院薬局、小売薬局、その他）

調査対象企業の例

  • Abbott Laboratories
  • Acetelion Ltd
  • Actelion Pharmaceuticals Ltd.
  • Aralez Pharmaceuticals Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Boryung Pharmaceutical Co., Ltd.
  • Cadila Healthcare Ltd.（Zydus Cadila）
  • Daiichi Sankyo Company Limited
  • Dongkwang Pharmaceutical Co., Ltd.
  • GlaxoSmithKline plc
  • Jiangsu Carephar Pharmaceutical
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30625

Global Duodenal Ulcer Treatment Market to Reach US$5.0 Billion by 2030

The global market for Duodenal Ulcer Treatment estimated at US$4.5 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 2.0% over the analysis period 2024-2030. Proton Pump Inhibitors, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the H2 Antagonists segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 3.8% CAGR

The Duodenal Ulcer Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$936.0 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Duodenal Ulcer Treatment Market - Key Trends & Drivers Summarized

Why Is Duodenal Ulcer Treatment Evolving into a Multi-Faceted Therapeutic Landscape?

Duodenal ulcer treatment has transitioned significantly from basic symptom relief to a comprehensive, multifactorial approach aimed at targeting the root causes, reducing recurrence, and preventing complications. Historically managed primarily through antacids and dietary modifications, modern treatment strategies now include an extensive range of pharmaceuticals such as proton pump inhibitors (PPIs), H2-receptor antagonists, antibiotics for Helicobacter pylori eradication, mucosal protectants, and combination therapies. This evolution has been primarily fueled by the discovery of H. pylori as a causative agent, fundamentally shifting the clinical paradigm toward bacterial eradication alongside acid suppression. Additionally, there’s a rising preference for triple and quadruple therapies that combine two antibiotics with acid suppressants to address antibiotic resistance and treatment failures. Over-the-counter availability of certain medications has increased accessibility, but also prompted renewed focus on physician-led treatment regimens to ensure long-term healing and compliance. The treatment scope now increasingly extends beyond pharmacology, with lifestyle counseling, dietary guidance, and follow-up endoscopy becoming integral to patient care. Innovations in drug delivery systems such as delayed-release capsules and orally disintegrating tablets are also improving patient adherence and outcomes. Collectively, the treatment landscape reflects an intersection of personalized medicine, infection management, and symptom control strategies.

How Is Technology Redefining Clinical Practices in Diagnosis and Therapy Monitoring?

Recent years have witnessed a marked improvement in the diagnostic and monitoring tools employed in duodenal ulcer treatment, transforming clinical decision-making and follow-up care. The widespread adoption of non-invasive diagnostic tools, such as urea breath tests, stool antigen tests, and advanced serological assays, has significantly increased the early detection rate of H. pylori infections-one of the primary culprits behind duodenal ulcers. In more complex or recurring cases, endoscopic technologies equipped with high-resolution imaging and biopsy capabilities are being utilized to not only diagnose but also monitor mucosal healing post-treatment. Digital health tools, including electronic health records and AI-assisted symptom tracking, are now enabling gastroenterologists to personalize treatment regimens more effectively. Moreover, pharmacogenomics is emerging as a key factor in determining antibiotic efficacy and resistance patterns in individual patients, ensuring that therapies are not only targeted but also yield sustainable remission. The rise of telemedicine platforms has also expanded access to gastrointestinal consultations, especially in remote regions, facilitating timely diagnosis and management of ulcer symptoms. Additionally, mobile health apps focused on medication reminders, dietary monitoring, and symptom logging are supporting patient adherence, which is critical in preventing recurrence. These technological enablers are reshaping how duodenal ulcers are treated, monitored, and managed across healthcare systems globally.

What Role Do Changing Lifestyle Patterns and Risk Profiles Play in Market Shifts?

Modern lifestyle changes have emerged as both a cause and a consequence of shifting treatment patterns in the duodenal ulcer landscape. Stress, irregular eating habits, increasing alcohol consumption, smoking, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) are significantly contributing to the incidence of duodenal ulcers worldwide. This epidemiological shift is leading to a broader demographic being affected, including younger age groups, women, and non-traditional patient segments. Consequently, the demand for early intervention strategies, preventive screening, and holistic treatment models is rising. The growing public awareness around gastrointestinal health, fueled by digital media and healthcare outreach programs, is encouraging more individuals to seek diagnosis at the onset of symptoms, boosting market demand for both diagnostics and therapeutics. Meanwhile, the healthcare industry’s focus on preventive care is expanding insurance coverage for gastrointestinal consultations and endoscopic procedures, reducing barriers to treatment. In parallel, pharmaceutical companies are investing in campaigns that promote awareness about the symptoms and risks of ulcers, further propelling diagnostic and therapeutic uptake. As patient expectations evolve toward faster recovery, fewer side effects, and minimal disruption to daily routines, treatment solutions are being recalibrated to provide comprehensive care with improved tolerability and reduced recurrence rates.

What Is Fueling the Expanding Demand in the Duodenal Ulcer Treatment Market?

The growth in the duodenal ulcer treatment market is driven by several factors linked to technological progress, changing treatment protocols, healthcare infrastructure improvements, and evolving patient behavior. One of the core growth drivers is the rising prevalence of H. pylori infections globally, particularly in developing nations where sanitation conditions are still improving, and awareness remains relatively low. This is compelling healthcare providers to invest in more widespread testing and targeted antibiotic therapies. Another major driver is the increasing resistance to standard antibiotics, prompting pharmaceutical innovation in the form of novel drug combinations, second-line treatment options, and new antibiotic classes. The broader availability and integration of advanced diagnostic tools such as real-time PCR tests and high-definition endoscopy are allowing for earlier and more accurate diagnoses, thereby increasing the number of patients receiving timely and effective treatment. Furthermore, the expansion of healthcare access in emerging markets-driven by public health initiatives, insurance penetration, and telehealth platforms-is significantly enhancing diagnosis and treatment rates. Patient demand for non-invasive, outpatient-based therapies is encouraging the development of convenient formulations and treatment regimens. Additionally, aging populations in regions like North America, Europe, and parts of Asia are more prone to ulcers due to increased NSAID use, driving consistent demand. These factors, together with the trend toward preventive healthcare and rising expenditure on gastrointestinal wellness, are collectively accelerating the growth of the global duodenal ulcer treatment market.

SCOPE OF STUDY:

The report analyzes the Duodenal Ulcer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Others); Administration Route (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Acetelion Ltd
  • Actelion Pharmaceuticals Ltd.
  • Aralez Pharmaceuticals Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Boryung Pharmaceutical Co., Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Daiichi Sankyo Company Limited
  • Dongkwang Pharmaceutical Co., Ltd.
  • GlaxoSmithKline plc
  • Jiangsu Carephar Pharmaceutical
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Duodenal Ulcer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Gastrointestinal Disorders Throws the Spotlight on the Demand for Duodenal Ulcer Treatment
    • Increased Diagnosis Rates Due to Enhanced Endoscopic Capabilities Propel Growth in Early-Stage Ulcer Management
    • Widespread Use of NSAIDs and H. pylori Infections Expand the Addressable Market for Pharmacological Interventions
    • Innovation in Combination Drug Therapies and PPIs Strengthens the Business Case for Fast and Sustained Ulcer Relief
    • Growing Focus on H. pylori Eradication Drives Adoption of Antibiotic-Based Treatment Regimens
    • Improved Awareness of GI Health and Lifestyle Risk Factors Accelerates Patient Willingness to Seek Timely Treatment
    • Introduction of Novel Acid Suppressants and Mucosal Protective Agents Spurs Product Innovation and Market Differentiation
    • Telemedicine and Digital GI Consultations Create New Avenues for Diagnosis, Prescription, and Therapy Adherence
    • Increased Focus on Evidence-Based Treatment Guidelines Reinforces Market Confidence in Standardized Care Protocols
    • Integration of Probiotics and Gut Microbiota Modulators Opens Adjunctive Therapy Opportunities in Recurrent Ulcer Management
    • Expansion of OTC Gastrointestinal Product Lines Fuels Demand for Self-Managed Relief and Preventive Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Duodenal Ulcer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Duodenal Ulcer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for H2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for H2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for H2 Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Duodenal Ulcer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Duodenal Ulcer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Duodenal Ulcer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Duodenal Ulcer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Duodenal Ulcer Treatment by Treatment - Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Duodenal Ulcer Treatment by Treatment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonists, Antibiotics and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Duodenal Ulcer Treatment by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Duodenal Ulcer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Duodenal Ulcer Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Duodenal Ulcer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION